145 related articles for article (PubMed ID: 1989647)
1. A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.
Wilson AP; Fox H; Scott IV; Lee H; Dent M; Golding PR
Br J Cancer; 1991 Jan; 63(1):102-8. PubMed ID: 1989647
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.
Yagi H; Miyamoto S; Tanaka Y; Sonoda K; Kobayashi H; Kishikawa T; Iwamoto R; Mekada E; Nakano H
Br J Cancer; 2005 May; 92(9):1737-45. PubMed ID: 15827558
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells.
Sowter HM; Corps AN; Smith SK
Int J Cancer; 1999 Nov; 83(4):476-80. PubMed ID: 10508482
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.
Mikuła-Pietrasik J; Uruski P; Matuszkiewicz K; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Cell Oncol (Dordr); 2016 Oct; 39(5):473-481. PubMed ID: 27444787
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
6. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer.
Rynne-Vidal A; Au-Yeung CL; Jiménez-Heffernan JA; Pérez-Lozano ML; Cremades-Jimeno L; Bárcena C; Cristóbal-García I; Fernández-Chacón C; Yeung TL; Mok SC; Sandoval P; López-Cabrera M
J Pathol; 2017 Jun; 242(2):140-151. PubMed ID: 28247413
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma.
Halperin R; Pansky M; Vaknin Z; Zehavi S; Bukovsky I; Schneider D;
Eur J Obstet Gynecol Reprod Biol; 2003 Oct; 110(2):207-10. PubMed ID: 12969585
[TBL] [Abstract][Full Text] [Related]
8. [A cytological study of peritoneal fluid obtained in gynecological laparotomies--with special reference to the diagnosis of ovarian malignancy].
Fujimaru J; Sato S
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jun; 36(6):917-26. PubMed ID: 6086789
[TBL] [Abstract][Full Text] [Related]
9. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.
Punnonen J; Heinonen PK; Kuoppala T; Jansen CT; Punnonen R
J Cancer Res Clin Oncol; 1991; 117(6):587-92. PubMed ID: 1744165
[TBL] [Abstract][Full Text] [Related]
10. Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells.
Wilson AP
Br J Cancer; 1989 Jun; 59(6):876-82. PubMed ID: 2786728
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
12. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.
Mills GB; May C; Hill M; Campbell S; Shaw P; Marks A
J Clin Invest; 1990 Sep; 86(3):851-5. PubMed ID: 2394835
[TBL] [Abstract][Full Text] [Related]
13. [Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors].
Strache RR; Göcze PM; Szábo DG; Büttner HH; Briese V; Kunze M; Csaba IF; Röpcke G
Zentralbl Gynakol; 1989; 111(11):749-54. PubMed ID: 2781888
[TBL] [Abstract][Full Text] [Related]
14. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.
Mills GB; May C; McGill M; Roifman CM; Mellors A
Cancer Res; 1988 Mar; 48(5):1066-71. PubMed ID: 3422589
[TBL] [Abstract][Full Text] [Related]
15. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
[TBL] [Abstract][Full Text] [Related]
16. Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
Wilhelm S; Schmitt M; Parkinson J; Kuhn W; Graeff H; Wilhelm OG
Int J Oncol; 1998 Oct; 13(4):645-51. PubMed ID: 9735390
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms.
Kutteh WH; Kutteh CC
Am J Obstet Gynecol; 1992 Dec; 167(6):1864-9. PubMed ID: 1471711
[TBL] [Abstract][Full Text] [Related]
18. Measurement of glycodelin A in fluids of benign ovarian cysts, borderline tumours and malignant ovarian cancer.
Bischof A; Briese V; Richter DU; Bergemann C; Friese K; Jeschke U
Anticancer Res; 2005; 25(3A):1639-44. PubMed ID: 16033074
[TBL] [Abstract][Full Text] [Related]
19. On the transforming growth factor beta-like activity of synthetic polypeptides comprising the amino-terminal sequence of human parathyroid hormone-related peptide.
Kikuchi H; Shigeno C; Lee K; Ohta S; Shiomi K; Ikeda T; Sone T; Dokoh S; Konishi J
Endocrinology; 1991 Mar; 128(3):1229-37. PubMed ID: 1999144
[TBL] [Abstract][Full Text] [Related]
20. Purification and biological properties of type beta transforming growth factor from mouse transformed cells.
Fernandez-Pol JA; Klos DJ; Grant GA
Cancer Res; 1986 Oct; 46(10):5153-61. PubMed ID: 3489522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
